TNFi (TNF-α inhibitors) are still frequently represented as the first line bDMARDs used in RA, PsA and AS, as well as in many non-rheumatic diseases such as IBD, psoriasis, immune-mediated uveitis and hidradenitis suppurativa [33,58]. Here, TNF is linked to inflammatory bowel disease.